Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gruppo Italiano Studio Linfomi
• Treatments: Bendamustine Hydrochloride; Rituximab

Criteria

Inclusion Criteria:

• patients with relapsed or refractory chronic lymphoproliferative disorders

• salvage treatment with bendamustine +/- rituximab

• age ≥ 18 years

Exclusion Criteria:

• previous treatment with bendamustine